First Tracks director plans $1.76M stock sale

Director Joe Anthony Ware has filed a Rule 144 notice to sell 39,265 TRAX common shares following a stock option exercise.

Rhea-AI Filing Summary

First Tracks Biotherapeutics, Inc. (TRAX) received a notice under Rule 144 that director Joe Anthony Ware plans to sell common stock. The planned sale covers 39,265 shares of common stock, expected to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services on or after September 2, 2026.

The shares are to be issued from a stock option exercise with the issuer as the counterparty and settled in cash. The filing lists an approximate aggregate market value of $1,758,145.35 for the shares and notes that 35,730,843 shares of the issuer’s common stock are outstanding, as context for the planned disposition.

Key Figures

Shares to be sold: 39,265 shares Approximate aggregate market value: $1,758,145.35 Shares outstanding: 35,730,843 shares +2 more

5 metrics

Shares to be sold 39,265 shares Common stock covered by the Rule 144 notice for director Joe Anthony Ware

Approximate aggregate market value $1,758,145.35 Value of 39,265 common shares subject to the planned Rule 144 sale

Shares outstanding 35,730,843 shares Outstanding common shares of First Tracks Biotherapeutics, Inc. as referenced in the notice

Planned sale date September 2, 2026 Date associated with the intended sale and option exercise

Security type Common stock Class of securities to be sold under Rule 144

Key Terms

Rule 144, stock option exercise, aggregate market value, securities to be sold

4 terms

Rule 144 regulatory

"Name of Person for Whose Account the Securities are To Be Sold | JOE ANTHONY WARE See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"Common | 09/02/2026 | Stock Option Exercise | Issuer | | | 39265"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services ... | 39265 | 1758145.35"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

securities to be sold regulatory

"144: Securities To Be Sold Common | 09/02/2026 | Stock Option Exercise"

FAQ

What does the Form 144 filing disclose for First Tracks Biotherapeutics, Inc. (TRAX)?

The Form 144 discloses that director Joe Anthony Ware intends to sell 39,265 shares of First Tracks Biotherapeutics common stock under Rule 144, with an approximate aggregate market value of $1,758,145.35, following a stock option exercise on or after September 2, 2026.

How many TRAX shares does the director plan to sell under this Form 144?

Director Joe Anthony Ware plans to sell 39,265 shares of First Tracks Biotherapeutics, Inc. common stock, as stated in the Rule 144 notice, with the transaction tied to a stock option exercise and an indicated sale date of September 2, 2026.

What is the approximate market value of the TRAX shares in this Form 144 filing?

The filing lists an approximate aggregate market value of $1,758,145.35 for the 39,265 common shares of First Tracks Biotherapeutics, Inc. that director Joe Anthony Ware intends to sell under Rule 144.

Who is the broker involved in the planned TRAX share sale under Rule 144?

The planned sale of First Tracks Biotherapeutics, Inc. common stock is to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, and is listed as the broker for the Rule 144 transaction.

How many TRAX shares are outstanding according to this Form 144 notice?

The Form 144 notice states that 35,730,843 shares of First Tracks Biotherapeutics, Inc. common stock are outstanding, providing context for the director’s planned sale of 39,265 shares under Rule 144.

On which market are the TRAX shares in this Form 144 filing listed to trade?

The shares referenced in the Form 144 filing for First Tracks Biotherapeutics, Inc. are listed as trading on NASDAQ, and the notice covers the intended resale of 39,265 common shares under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:13 PM Accepted by SEC EDGAR 09/02/2026 - 04:12 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001715429
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	FIRST TRACKS BIOTHERAPEUTICS, INC.
SEC File Number	001-43177
Address of Issuer	10770 Wateridge Circle, Suite 210 San Diego CALIFORNIA 92121
Phone	(858) 362-6295
Name of Person for Whose Account the Securities are To Be Sold	JOE ANTHONY WARE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	39265	1758145.35	35730843	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2026	Stock Option Exercise	Issuer			39265	09/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joe Anthony Ware
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)